AgingResearch.NewsJoin free

Accutar

CompanyUnited States

Accutar develops 4 assets, the furthest in phase 1 (AC699 in ER-positive/HER2-negative advanced or metastatic breast cancer). Mostly programmes acting on ESR1 and BTK; based in the United States.

4
Assets
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

4

  • AC699

    Degrades the estrogen receptor.

    Phase 1, ESR1, ER-positive/HER2-negative advanced or metastatic breast cancer

  • AC0176

    Degrades the androgen receptor.

    Stage not known

  • AC0676

    Degrades wild-type and C481S-mutant BTK.

    Stage not known, BTK

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • People2
  • Similar companies6

Intelligence